Skip to main content

Table 1 Clinical characteristics of nasopharyngeal carcinoma patients

From: Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model

  IC + CCRT(n = 220) CCRT + AC (n = 170) IC + CCRT + AC(n = 339) P value
Sex
Male 157 (71.4%) 128 (75.3%) 263 (77.6%) 0.251
Female 63 (28.6%) 42 (24.7%) 76 (22.4%)  
Age group, years
  ≤ 55 164 a (74.5%) 141 a,b (82.9%) 296 b (87.3%) 0.001
  > 55 56 a (25.5%) 29 a,b (17.1%) 43 b (12.7%)  
Staging
 III 85 a (38.6%) 88 b(51.8%) 135 a (39.8%) 0.033
 IVA 112 a (50.9%) 61 b (35.9%) 162 a (47.8%)  
 IVB 23 a(10.5%) 21 a(12.4%) 42 a(12.4%)  
EBV-DNA levels
  ≤ 1500 97 (54.8%) 51 (46.8%) 122 (51.3%) 0.418
  > 1500 80 (45.2%) 58 (53.2%) 116 (48.7%)  
Smoking
 Yes 91 (45.5%) 61 (37.9%) 137 (42.9%) 0.339
 No 109 (54.5%) 100 (62.1%) 182 (57.1%)  
Tumor category
 1 22 a (10.0%) 21 a (12.4%) 42 a (12.4%) 0.040
 2 28 a (12.7%) 40 b (23.5%) 46 a (13.6%)  
 3 54 a (24.5%) 39 a (22.9%) 75 a (22.1%)  
 4 116 a (52.7%) 70 a (41.2%) 176 a (51.9%)  
Node category
 0 12 (5.5%) 11 (6.5%) 20 (5.9%) 0.738
 1 54 (24.5%) 43 (25.3%) 66 (19.5%)  
 2 127 (57.7%) 94 (55.3%) 210 (61.9%)  
 3 27 (12.3%) 22 (12.9%) 43 (12.7%)  
  1. The total percentage may not add up to100% due to rounding. The clinical stages were evaluated according to the 7th edition of the American Joint Committee on Cancer TNM staging system. Data were expressed as n (%); P value was calculated by chi-square test. Each subscript letter denotes a subset of treatment categories whose column proportions do not differ significantly from each other at the 0.05 level